Echosens
Echosens is a French MedTech company founded in 2001, pioneering the future of liver health diagnostics. A trailblazer in its field, Echosens transformed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard for assessing and monitoring chronic liver disease.
FibroScan® is recognized worldwide as the gold standard for assessing liver fibrosis and steatosis, with over 6,270 peer-reviewed publications and more than 250 international guidelines.
Echosens distributes FibroScan® in more than 127 countries, enabling millions of non-invasive liver examinations to be performed worldwide
Our mission is clear: empowering medical professionals to manage liver health for simpler, faster, and better patient care. By replacing painful, invasive liver biopsies with a quick, painless exam, Echosens is making early diagnosis accessible at scale, at a time when liver diseases are reaching epidemic proportions globally.
Beyond diagnostics, Echosens partners with pharmaceutical companies to support clinical trials, patient stratification, and the development of new liver and metabolic treatments, accelerating breakthroughs that benefit millions of patients worldwide.
Echosens is not just building devices. It's reshaping how the world detects and fights liver disease, as the liver is an organ that suffers in silence.